This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Genitourinary Disease
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The goal of this clinical research study is to learn if Sutent® (sunitinib malate, SU011248) can control the disease in patients with germ cell tumors that are resistant to earlier treatment.

Provided treatments

  • Drug: Sunitinib Malate
Tris trial is registered with FDA with number: NCT00912912. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 5 volunteers for the current phase.
Official trial title:
Phase II Study of Sunitinib Malate in Refractory Germ Cell Tumors